{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:37:32Z","timestamp":1790505452810,"version":"4.1.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of tumor cells as vaccines in cancer immunotherapy is critically dependent on their capacity to initiate and amplify tumor-specific immunity. Optimal responses may require the modification of the tumor cells not only to increase their immunogenicity but also to improve their ability to recruit effector cells to the tumor sites or sites of tumor antigen exposure. It has been reported that CD40 cross-linking of acute lymphoblastic leukemia (ALL) cells significantly increases their immunogenicity and allows the generation and expansion of autologous antileukemia cytotoxic T lymphocytes. This study demonstrates that the CD40 ligation of these tumor cells also induces the secretion of the CC-chemokines MDC and TARC. Supernatants from malignant cells cultured in the presence of sCD40L promote the migration of activated T cells that express CCR4, the common specific receptor for MDC and TARC. More importantly, the supernatants from CD40-stimulated tumor cells also support the transendothelial migration of autologous CCR4+ antileukemia T cells. Therefore, the results demonstrate that the delivery to leukemia cells of a single physiologic signal, that is, CD40 cross-linking, simultaneously improves tumor cell immunogenicity and induces potent chemoattraction for T cells.<\/jats:p>","DOI":"10.1182\/blood.v98.3.533","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:47Z","timestamp":1027774007000},"page":"533-540","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":57,"title":["Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells"],"prefix":"10.1182","volume":"98","author":[{"given":"Paolo","family":"Ghia","sequence":"first","affiliation":[{"name":"From the Department of Adult Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Istituto per la Ricerca e la Cura del Cancro, Ospedale Mauriziano \u201cUmberto I,\u201d and University of Torino, Candiolo, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Basel Institute for Immunology, Basel, Switzerland; and Tokyo Medical School, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Transidico","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Istituto per la Ricerca e la Cura del Cancro, Ospedale Mauriziano \u201cUmberto I,\u201d and University of Torino, Candiolo, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Basel Institute for Immunology, Basel, Switzerland; and Tokyo Medical School, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Pedro","family":"Veiga","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Istituto per la Ricerca e la Cura del Cancro, Ospedale Mauriziano \u201cUmberto I,\u201d and University of Torino, Candiolo, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Basel Institute for Immunology, Basel, Switzerland; and Tokyo Medical School, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schaniel","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Istituto per la Ricerca e la Cura del Cancro, Ospedale Mauriziano \u201cUmberto I,\u201d and University of Torino, Candiolo, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Basel Institute for Immunology, Basel, Switzerland; and Tokyo Medical School, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Sallusto","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Istituto per la Ricerca e la Cura del Cancro, Ospedale Mauriziano \u201cUmberto I,\u201d and University of Torino, Candiolo, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Basel Institute for Immunology, Basel, Switzerland; and Tokyo Medical School, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Matsushima","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Istituto per la Ricerca e la Cura del Cancro, Ospedale Mauriziano \u201cUmberto I,\u201d and University of Torino, Candiolo, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Basel Institute for Immunology, Basel, Switzerland; and Tokyo Medical School, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Sallan","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Istituto per la Ricerca e la Cura del Cancro, Ospedale Mauriziano \u201cUmberto I,\u201d and University of Torino, Candiolo, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Basel Institute for Immunology, Basel, Switzerland; and Tokyo Medical School, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonius G.","family":"Rolink","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Istituto per la Ricerca e la Cura del Cancro, Ospedale Mauriziano \u201cUmberto I,\u201d and University of Torino, Candiolo, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Basel Institute for Immunology, Basel, Switzerland; and Tokyo Medical School, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mantovani","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Istituto per la Ricerca e la Cura del Cancro, Ospedale Mauriziano \u201cUmberto I,\u201d and University of Torino, Candiolo, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Basel Institute for Immunology, Basel, Switzerland; and Tokyo Medical School, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Nadler","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Istituto per la Ricerca e la Cura del Cancro, Ospedale Mauriziano \u201cUmberto I,\u201d and University of Torino, Candiolo, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Basel Institute for Immunology, Basel, Switzerland; and Tokyo Medical School, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo A.","family":"Cardoso","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Istituto per la Ricerca e la Cura del Cancro, Ospedale Mauriziano \u201cUmberto I,\u201d and University of Torino, Candiolo, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Basel Institute for Immunology, Basel, Switzerland; and Tokyo Medical School, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222520002900_B1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1074-7613(00)80165-X","article-title":"Chemokines: a new classification system and their role in immunity.","volume":"12","author":"Zlotnik","year":"2000","journal-title":"Immunity."},{"key":"2020021222520002900_B2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1146\/annurev.immunol.15.1.675","article-title":"Human chemokines: an update.","volume":"15","author":"Baggiolini","year":"1997","journal-title":"Annu Rev Immunol."},{"key":"2020021222520002900_B3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0167-5699(99)01469-3","article-title":"The chemokine system: redundancy for robust outputs.","volume":"20","author":"Mantovani","year":"1999","journal-title":"Immunol Today."},{"key":"2020021222520002900_B4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature."},{"key":"2020021222520002900_B5","first-page":"123","article-title":"The role of chemokine receptors in directing traffic of naive, type 1 and type 2 T cells.","volume":"246","author":"Sallusto","year":"1999","journal-title":"Curr Top Microbiol Immunol."},{"key":"2020021222520002900_B6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0167-5699(98)01346-2","article-title":"Chemokines and chemokine receptors in T-cell priming and Th1\/Th2-mediated responses.","volume":"19","author":"Sallusto","year":"1998","journal-title":"Immunol Today."},{"key":"2020021222520002900_B7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.187.1.129","article-title":"Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s.","volume":"187","author":"Bonecchi","year":"1998","journal-title":"J Exp Med."},{"key":"2020021222520002900_B8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1084\/jem.187.6.875","article-title":"Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes.","volume":"187","author":"Sallusto","year":"1998","journal-title":"J Exp Med."},{"key":"2020021222520002900_B9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4049\/jimmunol.161.2.547","article-title":"The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells.","volume":"161","author":"Zingoni","year":"1998","journal-title":"J Immunol."},{"key":"2020021222520002900_B10","doi-asserted-by":"crossref","first-page":"15036","DOI":"10.1074\/jbc.272.23.15036","article-title":"The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4.","volume":"272","author":"Imai","year":"1997","journal-title":"J Biol Chem."},{"key":"2020021222520002900_B11","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1074\/jbc.273.3.1764","article-title":"Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4.","volume":"273","author":"Imai","year":"1998","journal-title":"J Biol Chem."},{"key":"2020021222520002900_B12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/intimm\/11.1.81","article-title":"Selective recruitment of CCR4-bearing Th2 cells toward antigen- presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine.","volume":"11","author":"Imai","year":"1998","journal-title":"Int Immunol."},{"key":"2020021222520002900_B13","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.4049\/jimmunol.161.10.5111","article-title":"Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells.","volume":"161","author":"D'Ambrosio","year":"1998","journal-title":"J Immunol."},{"key":"2020021222520002900_B14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/nm1096-1090","article-title":"Combined chemokine and cytokine gene transfer enhances antitumor immunity.","volume":"2","author":"Dilloo","year":"1996","journal-title":"Nat Med."},{"key":"2020021222520002900_B15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF01516997","article-title":"Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors.","volume":"41","author":"Manome","year":"1995","journal-title":"Cancer Immunol Immunother."},{"key":"2020021222520002900_B16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.V88.1.41.41","article-title":"Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen.","volume":"88","author":"Cardoso","year":"1996","journal-title":"Blood."},{"key":"2020021222520002900_B17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood.V90.2.549","article-title":"Ex-vivo generation of anti-pre-B leukemia specific autologous cytolytic T cells.","volume":"90","author":"Cardoso","year":"1997","journal-title":"Blood."},{"key":"2020021222520002900_B18","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood.V94.10.3531.422k14_3531_3540","article-title":"Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies.","volume":"94","author":"Cardoso","year":"1999","journal-title":"Blood."},{"key":"2020021222520002900_B19","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1084\/jem.177.4.1209","article-title":"Soluble CD40-ligand can replace the normal T cell derived CD40-ligand signal to B cells in T-dependent activation.","volume":"177","author":"Lane","year":"1993","journal-title":"J Exp Med."},{"key":"2020021222520002900_B20","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1126\/science.272.5270.1939","article-title":"Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation.","volume":"272","author":"Levine","year":"1996","journal-title":"Science."},{"key":"2020021222520002900_B21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.1718038","article-title":"Regulation of transendothelial neutrophil migration by endogenous interleukin-8.","volume":"254","author":"Huber","year":"1991","journal-title":"Science."},{"key":"2020021222520002900_B22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0022-1759(95)00208-1","article-title":"Characterization of transendothelial chemotaxis of T lymphocytes.","volume":"188","author":"Roth","year":"1995","journal-title":"J Immunol Methods."},{"key":"2020021222520002900_B23","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1084\/jem.185.9.1595","article-title":"Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells.","volume":"185","author":"Godiska","year":"1997","journal-title":"J Exp Med."},{"key":"2020021222520002900_B24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-065X.1999.tb01332.x","article-title":"Cell-based vaccines for the stimulation of immunity to metastatic cancers.","volume":"170","author":"Ostrand-Rosenberg","year":"1999","journal-title":"Immunol Rev."},{"key":"2020021222520002900_B25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1385\/1-59259-222-8:359","article-title":"Antitumor immunity as therapy for human cancer.","volume-title":"Principles of Molecular Oncology.","author":"Cardoso","year":"2000"},{"key":"2020021222520002900_B26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/33340","article-title":"Chemokines and leukocyte traffic.","volume":"392","author":"Baggiolini","year":"1998","journal-title":"Nature."},{"key":"2020021222520002900_B27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/0952-7915(94)90075-2","article-title":"Tumor immunotherapy: the tumor cell as antigen-presenting cell.","volume":"6","author":"Ostrand-Rosenberg","year":"1994","journal-title":"Curr Opin Immunol."},{"key":"2020021222520002900_B28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0065-2776(08)60624-0","article-title":"Gene transfer as cancer therapy.","volume":"58","author":"Dranoff","year":"1995","journal-title":"Adv Immunol."},{"key":"2020021222520002900_B29","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0092-8674(05)80059-5","article-title":"Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.","volume":"71","author":"Chen","year":"1992","journal-title":"Cell."},{"key":"2020021222520002900_B30","first-page":"4890","article-title":"Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.","volume":"52","author":"Azuma","year":"1992","journal-title":"Cancer Res."},{"key":"2020021222520002900_B31","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1182\/blood.V84.10.3261.3261","article-title":"Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity.","volume":"84","author":"Guinan","year":"1994","journal-title":"Blood."},{"key":"2020021222520002900_B32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.181.2.619","article-title":"Major histocompatibility complex class II+ B7\u20131+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.","volume":"181","author":"Baskar","year":"1995","journal-title":"J Exp Med."},{"key":"2020021222520002900_B33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev.iy.13.040195.002151","article-title":"Paracrine cytokine adjuvants in cancer immunotherapy.","volume":"13","author":"Pardoll","year":"1995","journal-title":"Annu Rev Immunol."},{"key":"2020021222520002900_B34","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood.V85.9.2498.bloodjournal8592498","article-title":"Dependency on intercellular adhesion molecule recognition and local interleukin-2 provision in generation of an in vivo CD8+ T-cell immune response to murine myeloid leukemia.","volume":"85","author":"Boyer","year":"1995","journal-title":"Blood."},{"key":"2020021222520002900_B35","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.4049\/jimmunol.156.3.1126","article-title":"B7\u20131 is superior to B7\u20132 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity.","volume":"156","author":"Matulonis","year":"1996","journal-title":"J Immunol."},{"key":"2020021222520002900_B36","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V93.2.643","article-title":"Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors.","volume":"93","author":"Kutubuddin","year":"1999","journal-title":"Blood."},{"key":"2020021222520002900_B37","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.4049\/jimmunol.161.11.6238","article-title":"Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.","volume":"161","author":"Cao","year":"1998","journal-title":"J Immunol."},{"key":"2020021222520002900_B38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/6995","article-title":"Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity.","volume":"17","author":"Biragyn","year":"1999","journal-title":"Nat Biotechnol."},{"key":"2020021222520002900_B39","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/sj.bjc.6690164","article-title":"The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice.","volume":"79","author":"Mrowietz","year":"1999","journal-title":"Br J Cancer."},{"key":"2020021222520002900_B40","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0002-9440(10)65174-7","article-title":"Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma: a potential mechanism for high tumor aggressiveness.","volume":"155","author":"Kunz","year":"1999","journal-title":"Am J Pathol."},{"key":"2020021222520002900_B41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0165-2478(99)00043-7","article-title":"MCP-1 expression as a potential contributor to the high malignancy phenotype of murine mammary adenocarcinoma cells.","volume":"68","author":"Neumark","year":"1999","journal-title":"Immunol Lett."},{"key":"2020021222520002900_B42","first-page":"1168","article-title":"Expression of costimulatory molecules in human leukemias.","volume":"10","author":"Hirano","year":"1996","journal-title":"Leukemia."},{"key":"2020021222520002900_B43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1084\/jem.188.3.451","article-title":"Activated murine B lymphocytes and dendritic cells produce a novel CC chemokine which acts selectively on activated T cells.","volume":"188","author":"Schaniel","year":"1998","journal-title":"J Exp Med."},{"key":"2020021222520002900_B44","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1002\/(SICI)1521-4141(199909)29:09<2934::AID-IMMU2934>3.0.CO;2-Q","article-title":"Three chemokines with potential functions in T lymphocyte-independent and -dependent B lymphocyte stimulation.","volume":"29","author":"Schaniel","year":"1999","journal-title":"Eur J Immunol."},{"key":"2020021222520002900_B45","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1182\/blood.V94.3.845.415k09_845_852","article-title":"Serial analysis of gene expression in human monocyte-derived dendritic cells.","volume":"94","author":"Hashimoto","year":"1999","journal-title":"Blood."},{"key":"2020021222520002900_B46","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood.V94.3.837.413k02_837_844","article-title":"Serial analysis of gene expression in human monocytes and macrophages.","volume":"94","author":"Hashimoto","year":"1999","journal-title":"Blood."},{"key":"2020021222520002900_B47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0952-7915(99)80051-X","article-title":"Chemokine receptors in lymphoid organ homeostasis.","volume":"11","author":"Jung","year":"1999","journal-title":"Curr Opin Immunol."},{"key":"2020021222520002900_B48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0092-8674(00)81521-4","article-title":"The role of chemokines in regulating cell migration during humoral immune responses.","volume":"99","author":"Melchers","year":"1999","journal-title":"Cell."},{"key":"2020021222520002900_B49","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1084\/jem.180.4.1263","article-title":"Activation of human dendritic cells through CD40 cross-linking.","volume":"180","author":"Caux","year":"1994","journal-title":"J Exp Med."},{"key":"2020021222520002900_B50","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1084\/jem.182.6.1857","article-title":"Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals.","volume":"182","author":"Yellin","year":"1995","journal-title":"J Exp Med."},{"key":"2020021222520002900_B51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1084\/jem.182.1.33","article-title":"Expression of functional CD40 by vascular endothelial cells.","volume":"182","author":"Hollenbaugh","year":"1995","journal-title":"J Exp Med."},{"key":"2020021222520002900_B52","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.4049\/jimmunol.156.10.3737","article-title":"CD40 expressed on thymic epithelial cells provides costimulation for proliferation but not for apoptosis of human thymocytes.","volume":"156","author":"Ruggiero","year":"1996","journal-title":"J Immunol."},{"key":"2020021222520002900_B53","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.4049\/jimmunol.155.10.4588","article-title":"CD40 function in nonhematopoietic cells: nuclear factor kappa B mobilization and induction of IL-6 production.","volume":"155","author":"Hess","year":"1995","journal-title":"J Immunol."},{"key":"2020021222520002900_B54","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0140-6736(05)74011-3","article-title":"The balance of risk and benefit in gene-therapy trials [news].","volume":"355","author":"Barbour","year":"2000","journal-title":"Lancet."},{"key":"2020021222520002900_B55","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1126\/science.287.5453.591c","article-title":"Gene therapy on trial [letter].","volume":"287","author":"Miller","year":"2000","journal-title":"Science."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/3\/533\/1675796\/h8150100533.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/3\/533\/1675796\/h8150100533.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T20:11:20Z","timestamp":1682280680000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/98\/3\/533\/53269\/Chemoattractants-MDC-and-TARC-are-secreted-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8,1]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v98.3.533","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,8,1]]}}}